Business
Alligator Bioscience AB Reports Full Year Financial Results for 2025 and for Q4 2025 and Provides a Business Update
Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant upside in 2026. Mitazalimab validation: OPTIMIZE-1 biomarker results published in Cell Reports Medicine and REACtiVe-2 ...
About this update from Alligator Bioscience Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Rights issue completed: Approximately SEK 91 million (gross) raised in December, strengthening financial position with additional warrant upside in 2026.","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"Mitazalimab validation: OPTIMIZE-1 biomarker results published in Cell Reports Medicine and REACtiVe-2 data in Nature Communications.","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"Pipeline progress: U.S. patent granted for ATOR-4066, supporting long-term value beyond the lead program.","length":105,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":391,"olType":false},{"type":"text","content":"LUND, SE / ACCESS Newswire / February 12, 2026 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the third quarter of 2025 and provided a business update.","length":290,"tagName":"p"},{"type":"text","content":""The fourth quarter of 2025 was marked by continued execution on our strategy, focusing on advancing mitazalimab towards initiation of registrational trials, strengthening the scientific foundation of our pipeline, and increasing financial flexibility. While the external funding environment for biotech remains challenging, we have concentrated on areas within our control - generating high-quality data, maintaining operational discipline, and making focused investments that position the company to progress mitazalimab toward late-stage development." Søren Bregenholt, CEO of Alligator Bioscience","length":611,"tagName":"p"},{"type":"text","content":"BUSINESS UPDATEMitazalimab","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Scientific validation: Biomarker analyses from OPTIMIZE-1 were published in Cell Reports Medicine, deepening the understanding of mitazalimab's mechanism of action and links to clinical outcomes.","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional clinical publication: Data from the Phase 1 REACtiVe-2 study were published in Nature Communications, supporting mitazalimab's ability to activate systemic immune responses in metastatic pancreatic cancer.","length":220,"tagName":"p"}]},{"val":[{"type":"text","content":"External visibil...